Dhanvantri Jeev.

how big is Dhanvantri Jeev.?

As of Jun 06, Dhanvantri Jeevan Rekha Ltd has a market capitalization of 7.00 Cr, with recent net sales of 22.65 Cr and a net profit of 0.51 Cr for the latest four quarters. The company's balance sheet shows shareholder's funds of 9.47 Cr and total assets of 15.02 Cr as of Mar'24.

Market Cap: <BR>As of Jun 06, Dhanvantri Jeevan Rekha Ltd has a market capitalization of 7.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest 4 quarters, the company reported Net Sales of 22.65 Cr and a Net Profit of 0.51 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: <BR>The Standalone balance sheet for the latest annual period ending in Mar'24 shows Shareholder's Funds of 9.47 Cr and Total Assets of 15.02 Cr.

Who are the top shareholders of the Dhanvantri Jeev.?

The top shareholders of Dhanvantri Jeev include promoter Anil Elhence with 6.76% and public shareholder Rowena Sharma with 9.43%. Individual investors collectively hold 42.34%, with no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Dhanvantri Jeev include Anil Elhence, who is the promoter with the highest holding at 6.76%. The highest public shareholder is Rowena Sharma, holding 9.43%. Additionally, individual investors collectively hold 42.34% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

Who are in the management team of Dhanvantri Jeev.?

As of March 2022, the management team of Dhanvantri Jeev includes V S Phull and Shalini Sharma as Managing Directors, along with several non-executive and independent directors, totaling 12 members focused on governance and compliance.

As of March 2022, the management team of Dhanvantri Jeev includes the following individuals:<BR><BR>1. V S Phull - Managing Director<BR>2. Shalini Sharma - Managing Director<BR>3. Meenaakashi Elhence - Non-Executive & Non-Independent Director<BR>4. Premjit S Kashyap - Chairman (Non-Executive)<BR>5. Ashokkumar Singh Chaudhary - Non-Executive & Independent Director<BR>6. Ajay Rajpal - Non-Executive & Independent Director<BR>7. Ritika Bhandari - Company Secretary & Compliance Officer<BR>8. Anil Elhence - Director<BR>9. Rowena Sharma - Director<BR>10. Tulsi Prasad - Director<BR>11. Mohd Haaris - Director<BR>12. Amitabh Krishna Bhatia - Additional Director<BR><BR>This team comprises a mix of executive and non-executive roles, with a focus on governance and compliance.

Has Dhanvantri Jeev. declared dividend?

Dhanvantri Jeevan Rekha Ltd has declared a 4% dividend, amounting to 0.4100 per share, with an ex-date of September 15, 2011. However, the dividend yield is 0%, and total returns over various periods show significant price growth despite the lack of dividend income.

Dhanvantri Jeevan Rekha Ltd has declared a 4% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 4%<BR>- Amount per share: 0.4100<BR>- Ex-date: Sep-15-2011<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -27.48%, the dividend return was 0%, resulting in a total return of -27.48%.<BR><BR>In the 1-year period, the price return was 5.94%, the dividend return was 0%, resulting in a total return of 5.94%.<BR><BR>In the 2-year period, the price return was 39.92%, the dividend return was 0%, resulting in a total return of 39.92%.<BR><BR>In the 3-year period, the price return was 39.92%, the dividend return was 0%, resulting in a total return of 39.92%.<BR><BR>In the 4-year period, the price return was 204.44%, the dividend return was 0%, resulting in a total return of 204.44%.<BR><BR>In the 5-year period, the price return was 212.43%, the dividend return was 0%, resulting in a total return of 212.43%.<BR><BR>Overall, while Dhanvantri Jeevan Rekha Ltd has declared a dividend, the dividend yield remains at 0%. The total returns over various periods show a significant increase in price returns, particularly over the longer term, indicating potential growth despite the lack of dividend yield.

Who are the peers of the Dhanvantri Jeev.?

Dhanvantri Jeev.'s peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Ashram Online, Looks Health, and Dr Lalchand. Lab. Dhanvantri Jeev. has below average management risk and a 1-year return of -11.05%, higher than Dr Lalchand. Lab's -42.86% but lower than its other peers.

Peers: The peers of Dhanvantri Jeev. are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Ashram Online, Looks Health, and Dr Lalchand. Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Metropolis Healt, and the rest. Average management risk is present at Dr Lalchand. Lab, while Below Average management risk is noted for Dhanvantri Jeev. and the rest. Growth is Excellent at Dr Lal Pathlabs, while Average growth is seen at Poly Medicure, Indegene, and the rest. Below Average growth is reported for Syngene Intl., Vijaya Diagnost., Metropolis Healt, Dhanvantri Jeev., and the rest. Capital Structure is Excellent for Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and Metropolis Healt, while Good Capital Structure is noted for Dhanvantri Jeev. and Dr Lalchand. Lab.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.29%, while the lowest is Dr Lalchand. Lab at -42.86%. Dhanvantri Jeev.'s 1-year return is -11.05%, which is higher than Dr Lalchand. Lab but lower than the other peers. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, Ashram Online, and Dr Lalchand. Lab.

What is the technical trend for Dhanvantri Jeev.?

As of May 30, 2025, Dhanvantri Jeev's trend has shifted to a moderate bearish stance, supported by bearish momentum in the MACD, moving averages, and KST indicators, along with mildly bearish Bollinger Bands on both weekly and monthly time frames.

As of 30 May 2025, the technical trend for Dhanvantri Jeev has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD showing bearish momentum, daily moving averages confirming a bearish trend, and the KST on a weekly basis also indicating bearish conditions. The Bollinger Bands are mildly bearish on both weekly and monthly time frames, reinforcing the overall bearish outlook. The Dow Theory suggests a mildly bearish trend on the weekly chart, while the monthly chart shows no clear trend.

What does Dhanvantri Jeev. do?

Dhanvantri Jeevan Rekha Ltd is a micro-cap multi-speciality hospital established in 1993, offering diagnostic and therapeutic services. As of March 2025, it reported net sales of 58 Cr and a net profit of 0 Cr, with a market cap of INR 8 Cr.

Overview: <BR>Dhanvantri Jeevan Rekha Ltd is a multi-speciality hospital providing reliable diagnostic and therapeutic services in the healthcare services industry, categorized as a micro-cap company.<BR><BR>History: <BR>Incorporated on June 11, 1993, Dhanvantri Jeevan Rekha Ltd has been operational for approximately 30 years. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 58 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 8 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 8.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.24 <BR>Return on Equity: 5.20% <BR>Price to Book: 0.84 <BR><BR>Contact Details: <BR>Address: 1 Saket, Meerut, Uttar Pradesh: 250003 <BR>Tel: 91-0121-2648151/2648152 <BR>Email: dhanvantrihospital@gmail.com <BR>Website: http://www.djrl.org.in

How has been the historical performance of Dhanvantri Jeev.?

Dhanvantri Jeev has shown positive growth in net sales, increasing from 16.77 Cr in Mar'22 to 22.65 Cr in Mar'25, while profitability has fluctuated, with profit after tax improving from a loss of -1.42 Cr in Mar'21 to a profit of 0.51 Cr in Mar'25. Despite growth in sales, the company’s financial metrics indicate the need for ongoing monitoring and strategic management.

Answer:<BR>The historical performance of Dhanvantri Jeev shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Dhanvantri Jeev's net sales have increased from 16.77 Cr in Mar'22 to 22.65 Cr in Mar'25, indicating a positive growth trajectory. The total operating income followed a similar pattern, rising from 16.77 Cr in Mar'22 to 22.65 Cr in Mar'25. However, the operating profit (PBDIT) has shown volatility, peaking at 1.71 Cr in Mar'22 before declining to 1.12 Cr in Mar'25. Profit before tax also fluctuated, with a notable loss of -1.63 Cr in Mar'21, but rebounded to 0.56 Cr in Mar'25. Profit after tax improved from a loss of -1.42 Cr in Mar'21 to a profit of 0.51 Cr in Mar'25. The company's total assets decreased slightly from 15.02 Cr in Mar'24 to 14.75 Cr in Mar'25, while total liabilities also saw a decline from 15.02 Cr to 14.75 Cr in the same period. Cash flow from operating activities has been positive, with a net cash inflow of 2.00 Cr in Mar'24, reflecting improved liquidity. Overall, while Dhanvantri Jeev has experienced growth in sales and a recovery in profitability, its financial metrics indicate a need for continued monitoring and strategic management.

Is Dhanvantri Jeev. overvalued or undervalued?

As of November 17, 2025, Dhanvantri Jeev is considered risky and overvalued with a PE ratio of 103.48, low ROE of 1.00%, negative ROCE of -2.81%, and a PEG ratio of 0.00, despite a 23.17% stock return over the past year, suggesting caution for investors.

As of 17 November 2025, Dhanvantri Jeev's valuation grade has moved from very attractive to risky, indicating a significant shift in its perceived investment quality. The company is currently overvalued, with a price-to-earnings (PE) ratio of 103.48, which is substantially higher than peers like Apollo Hospitals at 64.41 and Max Healthcare at 77.22. Additionally, the EV to EBITDA ratio stands at 9.21, which, while not excessively high, still reflects a premium compared to the industry average.<BR><BR>In terms of performance metrics, Dhanvantri Jeev has a return on equity (ROE) of 1.00% and a return on capital employed (ROCE) of -2.81%, both of which are concerning and suggest inefficiencies in generating returns relative to its equity and capital. The company's PEG ratio is 0.00, indicating no growth expectations factored into its valuation, further supporting the conclusion that it is overvalued. Despite recent stock performance showing a 23.17% return over the past year compared to the Sensex's 9.50%, the underlying financial ratios and peer comparisons suggest that investors should approach Dhanvantri Jeev with caution.

Are Dhanvantri Jeevan Rekha Ltd latest results good or bad?

Dhanvantri Jeevan Rekha Ltd's latest Q3 FY26 results show strong revenue growth and a significant increase in net profit, but ongoing challenges with low return on equity and a high P/E ratio suggest caution for investors. Overall, the results present a mixed outlook.

Dhanvantri Jeevan Rekha Ltd's latest results for Q3 FY26 show a mix of positive developments and ongoing challenges. On the positive side, the company reported a net profit of ₹0.17 crore, which represents a remarkable 221.43% increase quarter-on-quarter and a 13.33% increase year-on-year. Additionally, net sales reached ₹7.27 crores, marking a strong 27.54% year-on-year growth and the highest quarterly figure in two years.<BR><BR>The operating margin improved to 3.99%, the highest in eight quarters, indicating a recovery in operational performance. However, despite these positive indicators, the company faces significant structural challenges. The average return on equity (ROE) remains low at 2.25%, which is below industry standards, and the return on capital employed (ROCE) is negative at -4.36%, suggesting issues with capital efficiency.<BR><BR>Moreover, the company's high P/E ratio of 104x raises concerns about its valuation, especially when compared to the healthcare services industry average of 59x. This valuation appears stretched given the company's underlying profitability and growth trajectory.<BR><BR>In summary, while the recent quarterly results indicate a recovery and growth in revenue, the company's persistent capital efficiency issues and high valuation present a mixed picture. Investors should weigh these factors carefully when assessing the company's performance.

Should I buy, sell or hold Dhanvantri Jeevan Rekha Ltd?

When is the next results date for Dhanvantri Jeevan Rekha Ltd?

The next results date for Dhanvantri Jeevan Rekha Ltd is 28 May 2026.

The next results date for Dhanvantri Jeevan Rekha Ltd is scheduled for 28 May 2026.

Why is Dhanvantri Jeevan Rekha Ltd falling/rising?

As of 20-May, Dhanvantri Jeevan Rekha Ltd's stock price is stable at 19.70 but has declined significantly by 25.15% over the past month, indicating underperformance compared to the Sensex. The company's weak financial metrics and declining investor participation suggest it is a risky investment.

As of 20-May, Dhanvantri Jeevan Rekha Ltd's stock price is currently stable at 19.70, showing no change (0.00%). However, the stock has experienced a significant decline over the past month, with a decrease of 25.15%, while the benchmark Sensex has only fallen by 4.08% during the same period. This underperformance is indicative of the stock's struggles.<BR><BR>The stock's performance over the last week has also been negative, down 4.00%, contrasting sharply with the Sensex, which has gained 0.95%. Year-to-date, Dhanvantri Jeevan Rekha Ltd has seen a decline of 21.33%, compared to the Sensex's loss of 11.62%. Despite a positive return of 15.20% over the past year, the company's profits have decreased by 27%, raising concerns about its long-term viability.<BR><BR>Several factors contribute to the stock's current situation. The company has reported weak long-term fundamental strength, with an average Return on Equity (ROE) of only 2.25%. Additionally, its operating profit has grown at a modest annual rate of 13.81% over the last five years, which is insufficient to instill confidence among investors. The company's ability to service its debt is also questionable, as indicated by a poor EBIT to Interest ratio of -0.02.<BR><BR>Moreover, the stock is trading below its moving averages across various time frames, suggesting a bearish trend. There has been a notable decline in investor participation, with delivery volume dropping by 89.67% against the five-day average. This erratic trading behavior, combined with the company's negative operating profits and weak financial metrics, positions Dhanvantri Jeevan Rekha Ltd as a risky investment, contributing to its falling stock price.

Which are the latest news on Dhanvantri Jeev.?